SlideShare une entreprise Scribd logo
1  sur  28
Télécharger pour lire hors ligne
Efficacy Assessment of Anthrax
Vaccines and Therapeutics in
Rabbits
Kelly Thomas
2
Human Anthrax Vaccines
There are two main types of anthrax vaccine for human use:
1. A cell free filtrate that contains antigenic proteins which are adsorbed or
precipitated using an aluminium-based adjuvant and have been obtained
from cultures of attenuated, avirulent strains of Bacillus anthracis. The
principal active ingredient is the Protective Antigen (PA) component of the
anthrax toxin complex. These vaccines include Anthrax Vaccine Adsorbed
(AVA) and Anthrax Vaccine Precipitated (AVP).
• AVA, adsorbed onto aluminium hydroxide
• AVP, precipitated onto aluminium potassium phosphate
2. A live attenuated vaccine containing spores from attenuated strains of B.
anthracis. The vaccine is administered as a two-dose regimen in the skin of
the shoulder by scarification.
http://www.who.int/vaccine_safety/initiative/tools/Anthrax_Vaccine_rates_information_sheet.pdf
Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
Next generation vaccines
3 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
Live spores
engineered to
express
relevant
antigens
Inactivated
spores plus
other
components
e.g. PA
Capsule
Antigen
delivery
methods
(microspheres,
nanoemulsion,
nanoparticles,
liposomes)
Live vectors
e.g.
Salmonella,
lactobacillus,
viruses
Adjuvants
(AVA)
Plant-based
vaccines
Next generation
vaccines:
rPAbased
4 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
rPA
vaccines
Subunit & other
components
Fusion
proteins
PA-LF
PA/LF
mutant
strains
PA
functional
domain
mutants
DNA
vaccine
Animal rule (FDA)
5 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
Approval Of New Drugs / Biological Products
When Human Efficacy Studies Are Not Ethical
Or Feasible
21 CFR Part 314 / 601
• Medical countermeasures for treatment / prevention of serious or life-
threatening conditions caused by exposure to lethal or permanently
disabling toxic biological, chemical, radiological or nuclear substances
• Efficacy studies cannot be conducted
• Safety evaluation is still required
Guidance for Industry, Product Development Under the Animal Rule. May 2014 & October 2015
Animal rule (FDA)
6 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
Approval based on evidence of
effectiveness from studies in animals
• Safety must have been established
• Adequate well-controlled animal studies to
establish benefit in humans
Requirements:
• Understanding of mechanism of toxicity and prevention/reduction by product
• Demonstrated in well-characterised animal model/in more than one animal
species predictive of human situation
• Animal study endpoint relates to desired benefit in humans
• Data allow the selection of effective human dose
Guidance for Industry, Product Development Under the Animal Rule. May 2014 and October 2015
Rabbit efficacy challenge model
• Most commonly used/accepted anthrax model (GUP & PEP)
• Recommended standardised schedule for testing Anthrax Vaccines for non-
inferiority to AVA
• NZW rabbits, 20-32 per group
• 2 vaccinations of 1/16 of a human dose of AVA
• Challenge with 200 LD50s of B. anthracis Ames via aerosol route
• Secondary readout serology (TNA NF50) day 0, 14, 28, 35, 42, 56, 69
7
Day 0 14 28 35 42 56 69,70
Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
Development of reagents and assays
• Challenge spores:
• Production
• Characterisation
• LD50 estimation
• Assay reagent generation:
• Rabbits vaccinated with anthrax vaccine
• Blood samples processed into large volumes of serum
• Assay development:
• Cell-based TNA adapted to measure immune responses in rabbits
• ELISA to measure antibody titres in rabbits
• New assays to study cell-mediated immunity
Efficacy of Anthrax Vaccines in rabbit models8 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
Rabbit efficacy challenge model
GUPApplication –AVP &AVA
• 2 dose regime replicated initially
• 20 rabbits vaccinated with 1/16 dose AVP
• 20 rabbits vaccinated with 1/16 dose AVA
• 4 rabbits vaccinated with saline
9 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
Day 0 14 28 35 42 56 70 84
Pre-challenge ear bleeds
• Serum:
• TNA
• Analysis in anti-PA, anti-LF and anti-EF ELISA
• Whole heparinised blood used to develop CMI assays:
• Flow cytometry – CD4, CD8, CD45
• Stimulate lymphocytes with rPA or ConA, RT-PCR for cytokines
• Whole blood cell count and viability, NC200 image cytometer
• Baseline blood streak
10 Efficacy of Anthrax Vaccines in rabbit models – Kelly Thomas
GUPApplication –AVP &AVA
Post-challenge samples
• Samples to calculate presented dose
• Ear bleed at onset of clinical signs?
• Animals monitored for clinical observations, temperature, weight
• 2ml ear bleeds taken where possible
• Serum stored – trigger to treat ECL assay under development
• Post-mortem blood streak – samples taken after all deaths (as a result of
challenge, euthanasia at humane endpoint or at scheduled cull). Allows cause
of death confirmation
11 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
GUPApplication –AVP &AVA
Necropsy
• Carried out on all survivors
• Carried out for animals that died mid-study where feasible
• Blood:
• Serum – for TNA and ELISA
• Bacteriology
• Lungs and lymph nodes:
• Bacteriology
• Histopathology
• Spleens:
• Bacteriology
• Histopathology
12
GUPApplication –AVP &AVA
Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
0
0.2
0.4
0.6
0.8
1
0 7 14 21 28 35 42 49 56 63 70
NF50
Study day
Median pre-challenge TNA NF50s
AVP
AVA
13 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
GUPApplication –AVP &AVA
14
Post-challenge survival
Days post-challenge
0 2 4 6 8 10 12 14
%survival
0
20
40
60
80
100
AVP
AVA
Saline
AVP
AVA
Saline
GUPApplication –AVP &AVA
Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
15 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
GUPApplication –AVP &AVA
0
20
40
60
80
100
0 2 4 6 8 10 12 14
Clinicalscoreas%ofmaximumpossiblescore
Time (days post-challenge)
Clinical score
AVP
AVA
Saline
Blood & tissues
• Bacteriology
• Blood and spleen of survivors negative for bacteria
• Bacteria enumerated in blood of some animals that died - highest level in control.
Some vaccinated animals positive, some negative
• All lungs contained bacteria. Highest in controls
• Highest bacterial counts in control spleen, some others positive
• Lymph nodes (where available) all <LOD
• Histology
• Control animal showed high level of bacteraemia, some lesions in spleen and lung
• More severe lesions in vaccinated animals
• More tissues in AVA group classified as ‘within normal limits’
16 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
GUPApplication –AVP &AVA
• Study design modified to 3 doses and included generic rPA vaccine
• 10 rabbits vaccinated with 1/16 dose AVP
• 10 rabbits vaccinated with 1/16 dose AVA
• 10 rabbits vaccinated with 10mg rPA with alum
• 4 rabbits vaccinated with saline
17
Day 0 28 56 70 98 112
Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
3 dose GUP study –AVP,AVA& rPA
0
0.4
0.8
1.2
1.6
2
0 14 28 42 56 70 84 98
TNANF50
Study day
Median pre-challenge NF50s
AVP
AVA
rPA&alum
18 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
3 dose GUP study –AVP,AVA& rPA
19 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
3 dose GUP study –AVP,AVA& rPA
Post-challenge survival
Days post-challenge
0 2 4 6 8 10 12 14
%survival
0
20
40
60
80
100
AVP
AVA
rPA&alum
Saline
20 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
3 dose GUP study –AVP,AVA& rPA
0
20
40
60
80
100
0 2 4 6 8 10 12 14
Clinicalscoreas%ofmaximumpossiblescore
Time (days post challenge)
Clinical score
AVP
AVA
rPA&alum
Saline
Blood & tissues
• Bacteriology:
• Bacteria in blood of controls. Most survivors negative
• Spleens of control animals all positive. Survivors negative
• Lungs of control animals contained highest level of bacteria. Some survivors’ lungs
positive, some negative
• Histopathology:
• Visible bacilli in most control spleens and lungs, not survivors
• Moderate lesions of disease in control spleens, absent/milder in survivors
• Moderate inflammation in lungs of controls. Some survivors showed distinct lesions,
limited/no inflammation in most survivors – especially rPA & alum group
• Most survivors showed tissue hyperplasia/cell infiltration - reactive/protective?
21 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
3 dose GUP study –AVP,AVA& rPA
• Study design based on previous publications
• Rabbits challenged with 200 LD50s Ames spores
• 30 rabbits received 50mg/kg levofloxacin once a day for 7 days from day 0
• 10 rabbits vaccinated with 1/16 dose AVP on day 0 and day 7
• 10 rabbits vaccinated with 1/16 dose AVA on day 0 and day 7
• 10 rabbits received saline injections on day 0 and day 7
• 4 controls
22
Day 0 7 16 21 30
PEPApplication –AVP &AVA
Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
Samples
• Enumeration of challenge material
• Ear bleeds taken on day 0, 7, 16 and 21 from all remaining animals
• TNA/ELISA
• ECL assay
• Streak plates
• Necropsy carried out on all survivors on day 30 (or some mid-study deaths):
• Serum
• Blood for bacteriology
• Spleen and lungs for bacteriology and histology
23
Dilution
OD
Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
PEPApplication –AVP &AVA
24
Post-challenge survival
Days post-challenge
0 5 10 15 20 25 30
%survival
0
20
40
60
80
100
AVP
AVA
Antibiotics
Saline
AVP & Antibiotic
AVA & Antibiotic
Antibiotic
Saline
PEPApplication –AVP &AVA
Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
25 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
PEPApplication –AVP &AVA
0
20
40
60
80
100
0 5 10 15 20 25 30
Clinicalscoreas%ofmaximumpossiblescore
Time (days post challenge)
Clinical score
AVP & Antibiotic
AVA & Antibiotic
Antibiotic
Saline
Blood & tissues
• Bacteriology:
• Blood streak plates positive from most premature deaths. Negative for survivors
• Lungs contained bacteria when animals died mid-study. Lungs of survivors
low/negative
• Bacteria in spleens of most mid-study deaths, survivors negative
• Histopathology:
• Visible bacteria in tissues of some premature deaths
• Sporadic lung, spleen and lymph node lesions. Generally worst in control animals,
moderate in antibiotic group – milder in vaccinated groups
• Different changes seen in vaccinated animals compared to controls/antibiotic only
– some may be protective response rather than disease related
26 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
PEPApplication –AVP &AVA
Rabbit studies - summary
• Rabbit model – widely used to study AV efficacy in US
• Developed gold standard rabbit model in-house at PHE
• Efficacy of range of Anthrax Vaccines demonstrated and compared
• Supplementary information gathered on tissue pathology & bacterial burden
• Developed assays to study immune responses/correlates of protection and for
rapid toxin detection – important for well-characterised model
• Modified GUP schedule as appropriate for test vaccine (can also modify route)
• Adapted model to show PEP benefits (can apply to new and existing vaccines)
Presentation title - edit in Header and Footer27 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
Acknowledgements
Vaccine Research Group
• Sue Charlton
• Bassam Hallis
• Phillip Brown
• Ines Vitoriano
• Nadina Wand
• Anna Pang
• Kim Steeds
• Debbie Powell
• Ross Fothergill
• Emma Kennedy
• Emily Hughes
• Rebecca Cobb
• Ester Schallinger
• Charlotte Ford
• Marilyn Aram
• Tom Slocombe
• Shea Creaven
• Lara Mason
• Jessica Fretwell
• Julia Sung
• Simon Eastham
28
Immunoassay Group
• Mary Matheson
Biodefense and Preclinical
Evaluation Group
• Julia Vipond
• Simon Funnell
• Helen Shuttleworth, Kerry Godwin,
Nicola Jones
Influenza Research Group
• Karen Gooch, Jennifer Logue, Kathryn
Ryan
Biological Investigations Group
• Irene Taylor
• Graham Hatch
• Susan Ryrie
Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits

Contenu connexe

Tendances

PPT Cirillo " Diagnostic laboratory news"
PPT Cirillo " Diagnostic laboratory news"PPT Cirillo " Diagnostic laboratory news"
PPT Cirillo " Diagnostic laboratory news"StopTb Italia
 
Assays of Rabies vaccine
Assays of Rabies vaccineAssays of Rabies vaccine
Assays of Rabies vaccineRam Kumar
 
Evaluation of anti-HIV potential in selected medicinal plants
Evaluation of anti-HIV potential in selected medicinal plantsEvaluation of anti-HIV potential in selected medicinal plants
Evaluation of anti-HIV potential in selected medicinal plantsTitas Mallick
 
CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...
CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...
CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...Eastern Pennsylvania Branch ASM
 
Newer methods in diagnosis of tuberculosis in children
Newer methods in diagnosis of tuberculosis in childrenNewer methods in diagnosis of tuberculosis in children
Newer methods in diagnosis of tuberculosis in childrenDr Naveen kumar
 
Advances in diagnostic technology
Advances in diagnostic technologyAdvances in diagnostic technology
Advances in diagnostic technologyRitasree Sarma
 
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSISRECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSISANGAN KARMAKAR
 
Interlaboratory comparison of results of an anthrax lethal toxin neutralizati...
Interlaboratory comparison of results of an anthrax lethal toxin neutralizati...Interlaboratory comparison of results of an anthrax lethal toxin neutralizati...
Interlaboratory comparison of results of an anthrax lethal toxin neutralizati...National Institute of Biologics
 
Profiling Hospital-Acquired Pathogens and Antibiotic Resistance Genes Webinar
Profiling Hospital-Acquired Pathogens and Antibiotic Resistance Genes WebinarProfiling Hospital-Acquired Pathogens and Antibiotic Resistance Genes Webinar
Profiling Hospital-Acquired Pathogens and Antibiotic Resistance Genes WebinarQIAGEN
 
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan DiseasesUsing In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan DiseasesSean Ekins
 
The New Xpert MTB/RIF Ultra:
The New Xpert MTB/RIF Ultra:The New Xpert MTB/RIF Ultra:
The New Xpert MTB/RIF Ultra:SystemOne
 
Newer investigations of tuberculosis
Newer investigations of tuberculosisNewer investigations of tuberculosis
Newer investigations of tuberculosisVishnu Ambareesh
 
Mario H. Skiadopoulos Presentation on "Evaluation of the Antibody Threshold o...
Mario H. Skiadopoulos Presentation on "Evaluation of the Antibody Threshold o...Mario H. Skiadopoulos Presentation on "Evaluation of the Antibody Threshold o...
Mario H. Skiadopoulos Presentation on "Evaluation of the Antibody Threshold o...Matthew Kirkby
 
Newer diagnostic methods for tuberculosis
Newer  diagnostic  methods for tuberculosis  Newer  diagnostic  methods for tuberculosis
Newer diagnostic methods for tuberculosis Shweta Anand
 
detect and identify common human bacterial pathogens in high purity water.
detect and identify common human bacterial pathogens in high purity water.detect and identify common human bacterial pathogens in high purity water.
detect and identify common human bacterial pathogens in high purity water.Saad Farooqi
 
Dr. Sid Thakur - Antimicrobial Resistance: Do We Know Everything?
Dr. Sid Thakur - Antimicrobial Resistance: Do We Know Everything?Dr. Sid Thakur - Antimicrobial Resistance: Do We Know Everything?
Dr. Sid Thakur - Antimicrobial Resistance: Do We Know Everything?John Blue
 

Tendances (20)

PPT Cirillo " Diagnostic laboratory news"
PPT Cirillo " Diagnostic laboratory news"PPT Cirillo " Diagnostic laboratory news"
PPT Cirillo " Diagnostic laboratory news"
 
Assays of Rabies vaccine
Assays of Rabies vaccineAssays of Rabies vaccine
Assays of Rabies vaccine
 
4
44
4
 
Evaluation of anti-HIV potential in selected medicinal plants
Evaluation of anti-HIV potential in selected medicinal plantsEvaluation of anti-HIV potential in selected medicinal plants
Evaluation of anti-HIV potential in selected medicinal plants
 
CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...
CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...
CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...
 
Newer methods in diagnosis of tuberculosis in children
Newer methods in diagnosis of tuberculosis in childrenNewer methods in diagnosis of tuberculosis in children
Newer methods in diagnosis of tuberculosis in children
 
Advances in diagnostic technology
Advances in diagnostic technologyAdvances in diagnostic technology
Advances in diagnostic technology
 
Xpert MTB/RIF Ultra newer technology past to future DIAGNOSIS OF TUBERCULOSIS
Xpert MTB/RIF Ultranewer technologypast to future DIAGNOSIS OF TUBERCULOSIS Xpert MTB/RIF Ultranewer technologypast to future DIAGNOSIS OF TUBERCULOSIS
Xpert MTB/RIF Ultra newer technology past to future DIAGNOSIS OF TUBERCULOSIS
 
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSISRECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
 
Tb newer diagnostics
Tb newer diagnosticsTb newer diagnostics
Tb newer diagnostics
 
Interlaboratory comparison of results of an anthrax lethal toxin neutralizati...
Interlaboratory comparison of results of an anthrax lethal toxin neutralizati...Interlaboratory comparison of results of an anthrax lethal toxin neutralizati...
Interlaboratory comparison of results of an anthrax lethal toxin neutralizati...
 
Profiling Hospital-Acquired Pathogens and Antibiotic Resistance Genes Webinar
Profiling Hospital-Acquired Pathogens and Antibiotic Resistance Genes WebinarProfiling Hospital-Acquired Pathogens and Antibiotic Resistance Genes Webinar
Profiling Hospital-Acquired Pathogens and Antibiotic Resistance Genes Webinar
 
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan DiseasesUsing In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
 
The New Xpert MTB/RIF Ultra:
The New Xpert MTB/RIF Ultra:The New Xpert MTB/RIF Ultra:
The New Xpert MTB/RIF Ultra:
 
Newer investigations of tuberculosis
Newer investigations of tuberculosisNewer investigations of tuberculosis
Newer investigations of tuberculosis
 
Mario H. Skiadopoulos Presentation on "Evaluation of the Antibody Threshold o...
Mario H. Skiadopoulos Presentation on "Evaluation of the Antibody Threshold o...Mario H. Skiadopoulos Presentation on "Evaluation of the Antibody Threshold o...
Mario H. Skiadopoulos Presentation on "Evaluation of the Antibody Threshold o...
 
Newer diagnostic methods for tuberculosis
Newer  diagnostic  methods for tuberculosis  Newer  diagnostic  methods for tuberculosis
Newer diagnostic methods for tuberculosis
 
detect and identify common human bacterial pathogens in high purity water.
detect and identify common human bacterial pathogens in high purity water.detect and identify common human bacterial pathogens in high purity water.
detect and identify common human bacterial pathogens in high purity water.
 
Dr. Sid Thakur - Antimicrobial Resistance: Do We Know Everything?
Dr. Sid Thakur - Antimicrobial Resistance: Do We Know Everything?Dr. Sid Thakur - Antimicrobial Resistance: Do We Know Everything?
Dr. Sid Thakur - Antimicrobial Resistance: Do We Know Everything?
 
Animal experiments
Animal experimentsAnimal experiments
Animal experiments
 

En vedette

Lec 21 22 Zoonotic Diseases
Lec 21 22 Zoonotic DiseasesLec 21 22 Zoonotic Diseases
Lec 21 22 Zoonotic DiseasesDrAlana
 
Milk borne disease
Milk borne diseaseMilk borne disease
Milk borne diseaseArun Raj
 
Bacterial food born diseases
Bacterial food born diseasesBacterial food born diseases
Bacterial food born diseasesDalia El-Shafei
 
FOOD BORNE DISEASES & IT'S PREVENTION
FOOD BORNE DISEASES & IT'S PREVENTIONFOOD BORNE DISEASES & IT'S PREVENTION
FOOD BORNE DISEASES & IT'S PREVENTIONSharjil Mahmood
 
Study of Microorganism in Milk(Dairy microbiology)
Study of Microorganism in Milk(Dairy microbiology)Study of Microorganism in Milk(Dairy microbiology)
Study of Microorganism in Milk(Dairy microbiology)Saugat Bhattacharjee
 

En vedette (9)

Lec 21 22 Zoonotic Diseases
Lec 21 22 Zoonotic DiseasesLec 21 22 Zoonotic Diseases
Lec 21 22 Zoonotic Diseases
 
Milk borne disease
Milk borne diseaseMilk borne disease
Milk borne disease
 
Foot and mouth disease
Foot and mouth diseaseFoot and mouth disease
Foot and mouth disease
 
Bacterial food born diseases
Bacterial food born diseasesBacterial food born diseases
Bacterial food born diseases
 
FOOD BORNE DISEASES & IT'S PREVENTION
FOOD BORNE DISEASES & IT'S PREVENTIONFOOD BORNE DISEASES & IT'S PREVENTION
FOOD BORNE DISEASES & IT'S PREVENTION
 
Zoonoses
ZoonosesZoonoses
Zoonoses
 
Anthrax
AnthraxAnthrax
Anthrax
 
Study of Microorganism in Milk(Dairy microbiology)
Study of Microorganism in Milk(Dairy microbiology)Study of Microorganism in Milk(Dairy microbiology)
Study of Microorganism in Milk(Dairy microbiology)
 
Dairy microbiology
Dairy microbiologyDairy microbiology
Dairy microbiology
 

Similaire à Kelly Thomas presentation on "KT efficacy of anthrax vaccines in rabbits"

4. Friday Monogastric Sessions prof john pluske murdoch university - amr in...
4. Friday Monogastric Sessions prof john pluske   murdoch university - amr in...4. Friday Monogastric Sessions prof john pluske   murdoch university - amr in...
4. Friday Monogastric Sessions prof john pluske murdoch university - amr in...2damcreative
 
Dr. Rebecca Pentecost: Pennsylvania Llama and Alpaca Association 2011
Dr. Rebecca Pentecost: Pennsylvania Llama and Alpaca Association 2011 Dr. Rebecca Pentecost: Pennsylvania Llama and Alpaca Association 2011
Dr. Rebecca Pentecost: Pennsylvania Llama and Alpaca Association 2011 changingconnections
 
Rebecca Pentecost DVM: PLAA 2011 Keynote Slides
Rebecca Pentecost DVM: PLAA 2011 Keynote SlidesRebecca Pentecost DVM: PLAA 2011 Keynote Slides
Rebecca Pentecost DVM: PLAA 2011 Keynote SlidesRJ Stangherlin
 
Dr. Paul Hauer - National Veterinary Services Laboratories (NVSL) Update
Dr. Paul Hauer - National Veterinary Services Laboratories (NVSL) UpdateDr. Paul Hauer - National Veterinary Services Laboratories (NVSL) Update
Dr. Paul Hauer - National Veterinary Services Laboratories (NVSL) UpdateJohn Blue
 
Killer in the Kunai by Dr. David Williams
Killer in the Kunai by Dr. David WilliamsKiller in the Kunai by Dr. David Williams
Killer in the Kunai by Dr. David WilliamsBio-Ken
 
Dr. Pete Thomas - Antibiotic Injection of Piglets-Treatment, Control or Preve...
Dr. Pete Thomas - Antibiotic Injection of Piglets-Treatment, Control or Preve...Dr. Pete Thomas - Antibiotic Injection of Piglets-Treatment, Control or Preve...
Dr. Pete Thomas - Antibiotic Injection of Piglets-Treatment, Control or Preve...John Blue
 
bacteremia-slides.pptx
bacteremia-slides.pptxbacteremia-slides.pptx
bacteremia-slides.pptxAntnaSinek
 
The problem and Its Background
The problem and Its BackgroundThe problem and Its Background
The problem and Its BackgroundMoris Santos
 
Screening methods of immunomodulators by shivam diwaker
Screening methods of immunomodulators by shivam diwakerScreening methods of immunomodulators by shivam diwaker
Screening methods of immunomodulators by shivam diwakerShivam Diwaker
 
ELISA_as_a_Diagnostic_Tool_Influenza.ppt
ELISA_as_a_Diagnostic_Tool_Influenza.pptELISA_as_a_Diagnostic_Tool_Influenza.ppt
ELISA_as_a_Diagnostic_Tool_Influenza.pptLani Manahan
 
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptxwhat is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptxPathKind Labs
 
SARS clinical features treatment and complications
SARS clinical features treatment and complicationsSARS clinical features treatment and complications
SARS clinical features treatment and complicationsprasanna lakshmi sangineni
 
pharmacology practice school report.pptx
pharmacology practice school report.pptxpharmacology practice school report.pptx
pharmacology practice school report.pptxPharama slide share
 
pharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdf
pharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdfpharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdf
pharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdfManishJaat9
 
Dr. Mike Apley - Where Are We With Resistance in Vet Medicine? Are We Having ...
Dr. Mike Apley - Where Are We With Resistance in Vet Medicine? Are We Having ...Dr. Mike Apley - Where Are We With Resistance in Vet Medicine? Are We Having ...
Dr. Mike Apley - Where Are We With Resistance in Vet Medicine? Are We Having ...John Blue
 
Management guidelines pyogenic meningitis
Management guidelines pyogenic meningitisManagement guidelines pyogenic meningitis
Management guidelines pyogenic meningitisNeurologyKota
 
Dr. Albert Rovira - Diagnostic View of Porcine Epidemic Diarrhea Virus
Dr. Albert Rovira - Diagnostic View of Porcine Epidemic Diarrhea VirusDr. Albert Rovira - Diagnostic View of Porcine Epidemic Diarrhea Virus
Dr. Albert Rovira - Diagnostic View of Porcine Epidemic Diarrhea VirusJohn Blue
 

Similaire à Kelly Thomas presentation on "KT efficacy of anthrax vaccines in rabbits" (20)

4. Friday Monogastric Sessions prof john pluske murdoch university - amr in...
4. Friday Monogastric Sessions prof john pluske   murdoch university - amr in...4. Friday Monogastric Sessions prof john pluske   murdoch university - amr in...
4. Friday Monogastric Sessions prof john pluske murdoch university - amr in...
 
Dr. Rebecca Pentecost: Pennsylvania Llama and Alpaca Association 2011
Dr. Rebecca Pentecost: Pennsylvania Llama and Alpaca Association 2011 Dr. Rebecca Pentecost: Pennsylvania Llama and Alpaca Association 2011
Dr. Rebecca Pentecost: Pennsylvania Llama and Alpaca Association 2011
 
Rebecca Pentecost DVM: PLAA 2011 Keynote Slides
Rebecca Pentecost DVM: PLAA 2011 Keynote SlidesRebecca Pentecost DVM: PLAA 2011 Keynote Slides
Rebecca Pentecost DVM: PLAA 2011 Keynote Slides
 
Dr. Paul Hauer - National Veterinary Services Laboratories (NVSL) Update
Dr. Paul Hauer - National Veterinary Services Laboratories (NVSL) UpdateDr. Paul Hauer - National Veterinary Services Laboratories (NVSL) Update
Dr. Paul Hauer - National Veterinary Services Laboratories (NVSL) Update
 
Killer in the Kunai by Dr. David Williams
Killer in the Kunai by Dr. David WilliamsKiller in the Kunai by Dr. David Williams
Killer in the Kunai by Dr. David Williams
 
viral diarrhoea.ppt
viral diarrhoea.pptviral diarrhoea.ppt
viral diarrhoea.ppt
 
FMDV
FMDVFMDV
FMDV
 
Dr. Pete Thomas - Antibiotic Injection of Piglets-Treatment, Control or Preve...
Dr. Pete Thomas - Antibiotic Injection of Piglets-Treatment, Control or Preve...Dr. Pete Thomas - Antibiotic Injection of Piglets-Treatment, Control or Preve...
Dr. Pete Thomas - Antibiotic Injection of Piglets-Treatment, Control or Preve...
 
bacteremia-slides.pptx
bacteremia-slides.pptxbacteremia-slides.pptx
bacteremia-slides.pptx
 
The problem and Its Background
The problem and Its BackgroundThe problem and Its Background
The problem and Its Background
 
Screening methods of immunomodulators by shivam diwaker
Screening methods of immunomodulators by shivam diwakerScreening methods of immunomodulators by shivam diwaker
Screening methods of immunomodulators by shivam diwaker
 
ELISA_as_a_Diagnostic_Tool_Influenza.ppt
ELISA_as_a_Diagnostic_Tool_Influenza.pptELISA_as_a_Diagnostic_Tool_Influenza.ppt
ELISA_as_a_Diagnostic_Tool_Influenza.ppt
 
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptxwhat is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
 
20161003 rabies
20161003 rabies20161003 rabies
20161003 rabies
 
SARS clinical features treatment and complications
SARS clinical features treatment and complicationsSARS clinical features treatment and complications
SARS clinical features treatment and complications
 
pharmacology practice school report.pptx
pharmacology practice school report.pptxpharmacology practice school report.pptx
pharmacology practice school report.pptx
 
pharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdf
pharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdfpharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdf
pharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdf
 
Dr. Mike Apley - Where Are We With Resistance in Vet Medicine? Are We Having ...
Dr. Mike Apley - Where Are We With Resistance in Vet Medicine? Are We Having ...Dr. Mike Apley - Where Are We With Resistance in Vet Medicine? Are We Having ...
Dr. Mike Apley - Where Are We With Resistance in Vet Medicine? Are We Having ...
 
Management guidelines pyogenic meningitis
Management guidelines pyogenic meningitisManagement guidelines pyogenic meningitis
Management guidelines pyogenic meningitis
 
Dr. Albert Rovira - Diagnostic View of Porcine Epidemic Diarrhea Virus
Dr. Albert Rovira - Diagnostic View of Porcine Epidemic Diarrhea VirusDr. Albert Rovira - Diagnostic View of Porcine Epidemic Diarrhea Virus
Dr. Albert Rovira - Diagnostic View of Porcine Epidemic Diarrhea Virus
 

Dernier

biosynthesis of the cell wall and antibiotics
biosynthesis of the cell wall and antibioticsbiosynthesis of the cell wall and antibiotics
biosynthesis of the cell wall and antibioticsSafaFallah
 
Krishi Vigyan Kendras - कृषि विज्ञान केंद्र
Krishi Vigyan Kendras - कृषि विज्ञान केंद्रKrishi Vigyan Kendras - कृषि विज्ञान केंद्र
Krishi Vigyan Kendras - कृषि विज्ञान केंद्रKrashi Coaching
 
Basic Concepts in Pharmacology in molecular .pptx
Basic Concepts in Pharmacology in molecular  .pptxBasic Concepts in Pharmacology in molecular  .pptx
Basic Concepts in Pharmacology in molecular .pptxVijayaKumarR28
 
Pests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdf
Pests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdfPests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdf
Pests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdfPirithiRaju
 
KeyBio pipeline for bioinformatics and data science
KeyBio pipeline for bioinformatics and data scienceKeyBio pipeline for bioinformatics and data science
KeyBio pipeline for bioinformatics and data scienceLayne Sadler
 
001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...
001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...
001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...marwaahmad357
 
Pests of Redgram_Identification, Binomics_Dr.UPR
Pests of Redgram_Identification, Binomics_Dr.UPRPests of Redgram_Identification, Binomics_Dr.UPR
Pests of Redgram_Identification, Binomics_Dr.UPRPirithiRaju
 
Alternative system of medicine herbal drug technology syllabus
Alternative system of medicine herbal drug technology syllabusAlternative system of medicine herbal drug technology syllabus
Alternative system of medicine herbal drug technology syllabusPradnya Wadekar
 
M.Pharm - Question Bank - Drug Delivery Systems
M.Pharm - Question Bank - Drug Delivery SystemsM.Pharm - Question Bank - Drug Delivery Systems
M.Pharm - Question Bank - Drug Delivery SystemsSumathi Arumugam
 
Controlling Parameters of Carbonate platform Environment
Controlling Parameters of Carbonate platform EnvironmentControlling Parameters of Carbonate platform Environment
Controlling Parameters of Carbonate platform EnvironmentRahulVishwakarma71547
 
Q3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptx
Q3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptxQ3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptx
Q3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptxArdeniel
 
Substances in Common Use for Shahu College Screening Test
Substances in Common Use for Shahu College Screening TestSubstances in Common Use for Shahu College Screening Test
Substances in Common Use for Shahu College Screening TestAkashDTejwani
 
Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...
Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...
Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...Sérgio Sacani
 
soft skills question paper set for bba ca
soft skills question paper set for bba casoft skills question paper set for bba ca
soft skills question paper set for bba caohsadfeeling
 
Lehninger_Chapter 17_Fatty acid Oxid.ppt
Lehninger_Chapter 17_Fatty acid Oxid.pptLehninger_Chapter 17_Fatty acid Oxid.ppt
Lehninger_Chapter 17_Fatty acid Oxid.pptSachin Teotia
 
PSP3 employability assessment form .docx
PSP3 employability assessment form .docxPSP3 employability assessment form .docx
PSP3 employability assessment form .docxmarwaahmad357
 
SCIENCE 6 QUARTER 3 REVIEWER(FRICTION, GRAVITY, ENERGY AND SPEED).pptx
SCIENCE 6 QUARTER 3 REVIEWER(FRICTION, GRAVITY, ENERGY AND SPEED).pptxSCIENCE 6 QUARTER 3 REVIEWER(FRICTION, GRAVITY, ENERGY AND SPEED).pptx
SCIENCE 6 QUARTER 3 REVIEWER(FRICTION, GRAVITY, ENERGY AND SPEED).pptxROVELYNEDELUNA3
 
Pests of wheat_Identification, Bionomics, Damage symptoms, IPM_Dr.UPR.pdf
Pests of wheat_Identification, Bionomics, Damage symptoms, IPM_Dr.UPR.pdfPests of wheat_Identification, Bionomics, Damage symptoms, IPM_Dr.UPR.pdf
Pests of wheat_Identification, Bionomics, Damage symptoms, IPM_Dr.UPR.pdfPirithiRaju
 

Dernier (20)

biosynthesis of the cell wall and antibiotics
biosynthesis of the cell wall and antibioticsbiosynthesis of the cell wall and antibiotics
biosynthesis of the cell wall and antibiotics
 
Krishi Vigyan Kendras - कृषि विज्ञान केंद्र
Krishi Vigyan Kendras - कृषि विज्ञान केंद्रKrishi Vigyan Kendras - कृषि विज्ञान केंद्र
Krishi Vigyan Kendras - कृषि विज्ञान केंद्र
 
Basic Concepts in Pharmacology in molecular .pptx
Basic Concepts in Pharmacology in molecular  .pptxBasic Concepts in Pharmacology in molecular  .pptx
Basic Concepts in Pharmacology in molecular .pptx
 
Pests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdf
Pests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdfPests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdf
Pests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdf
 
KeyBio pipeline for bioinformatics and data science
KeyBio pipeline for bioinformatics and data scienceKeyBio pipeline for bioinformatics and data science
KeyBio pipeline for bioinformatics and data science
 
001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...
001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...
001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...
 
Pests of Redgram_Identification, Binomics_Dr.UPR
Pests of Redgram_Identification, Binomics_Dr.UPRPests of Redgram_Identification, Binomics_Dr.UPR
Pests of Redgram_Identification, Binomics_Dr.UPR
 
Alternative system of medicine herbal drug technology syllabus
Alternative system of medicine herbal drug technology syllabusAlternative system of medicine herbal drug technology syllabus
Alternative system of medicine herbal drug technology syllabus
 
M.Pharm - Question Bank - Drug Delivery Systems
M.Pharm - Question Bank - Drug Delivery SystemsM.Pharm - Question Bank - Drug Delivery Systems
M.Pharm - Question Bank - Drug Delivery Systems
 
Controlling Parameters of Carbonate platform Environment
Controlling Parameters of Carbonate platform EnvironmentControlling Parameters of Carbonate platform Environment
Controlling Parameters of Carbonate platform Environment
 
Q3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptx
Q3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptxQ3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptx
Q3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptx
 
Applying Cheminformatics to Develop a Structure Searchable Database of Analyt...
Applying Cheminformatics to Develop a Structure Searchable Database of Analyt...Applying Cheminformatics to Develop a Structure Searchable Database of Analyt...
Applying Cheminformatics to Develop a Structure Searchable Database of Analyt...
 
Substances in Common Use for Shahu College Screening Test
Substances in Common Use for Shahu College Screening TestSubstances in Common Use for Shahu College Screening Test
Substances in Common Use for Shahu College Screening Test
 
Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...
Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...
Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...
 
soft skills question paper set for bba ca
soft skills question paper set for bba casoft skills question paper set for bba ca
soft skills question paper set for bba ca
 
Cheminformatics tools supporting dissemination of data associated with US EPA...
Cheminformatics tools supporting dissemination of data associated with US EPA...Cheminformatics tools supporting dissemination of data associated with US EPA...
Cheminformatics tools supporting dissemination of data associated with US EPA...
 
Lehninger_Chapter 17_Fatty acid Oxid.ppt
Lehninger_Chapter 17_Fatty acid Oxid.pptLehninger_Chapter 17_Fatty acid Oxid.ppt
Lehninger_Chapter 17_Fatty acid Oxid.ppt
 
PSP3 employability assessment form .docx
PSP3 employability assessment form .docxPSP3 employability assessment form .docx
PSP3 employability assessment form .docx
 
SCIENCE 6 QUARTER 3 REVIEWER(FRICTION, GRAVITY, ENERGY AND SPEED).pptx
SCIENCE 6 QUARTER 3 REVIEWER(FRICTION, GRAVITY, ENERGY AND SPEED).pptxSCIENCE 6 QUARTER 3 REVIEWER(FRICTION, GRAVITY, ENERGY AND SPEED).pptx
SCIENCE 6 QUARTER 3 REVIEWER(FRICTION, GRAVITY, ENERGY AND SPEED).pptx
 
Pests of wheat_Identification, Bionomics, Damage symptoms, IPM_Dr.UPR.pdf
Pests of wheat_Identification, Bionomics, Damage symptoms, IPM_Dr.UPR.pdfPests of wheat_Identification, Bionomics, Damage symptoms, IPM_Dr.UPR.pdf
Pests of wheat_Identification, Bionomics, Damage symptoms, IPM_Dr.UPR.pdf
 

Kelly Thomas presentation on "KT efficacy of anthrax vaccines in rabbits"

  • 1. Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits Kelly Thomas
  • 2. 2 Human Anthrax Vaccines There are two main types of anthrax vaccine for human use: 1. A cell free filtrate that contains antigenic proteins which are adsorbed or precipitated using an aluminium-based adjuvant and have been obtained from cultures of attenuated, avirulent strains of Bacillus anthracis. The principal active ingredient is the Protective Antigen (PA) component of the anthrax toxin complex. These vaccines include Anthrax Vaccine Adsorbed (AVA) and Anthrax Vaccine Precipitated (AVP). • AVA, adsorbed onto aluminium hydroxide • AVP, precipitated onto aluminium potassium phosphate 2. A live attenuated vaccine containing spores from attenuated strains of B. anthracis. The vaccine is administered as a two-dose regimen in the skin of the shoulder by scarification. http://www.who.int/vaccine_safety/initiative/tools/Anthrax_Vaccine_rates_information_sheet.pdf Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
  • 3. Next generation vaccines 3 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits Live spores engineered to express relevant antigens Inactivated spores plus other components e.g. PA Capsule Antigen delivery methods (microspheres, nanoemulsion, nanoparticles, liposomes) Live vectors e.g. Salmonella, lactobacillus, viruses Adjuvants (AVA) Plant-based vaccines
  • 4. Next generation vaccines: rPAbased 4 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits rPA vaccines Subunit & other components Fusion proteins PA-LF PA/LF mutant strains PA functional domain mutants DNA vaccine
  • 5. Animal rule (FDA) 5 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits Approval Of New Drugs / Biological Products When Human Efficacy Studies Are Not Ethical Or Feasible 21 CFR Part 314 / 601 • Medical countermeasures for treatment / prevention of serious or life- threatening conditions caused by exposure to lethal or permanently disabling toxic biological, chemical, radiological or nuclear substances • Efficacy studies cannot be conducted • Safety evaluation is still required Guidance for Industry, Product Development Under the Animal Rule. May 2014 & October 2015
  • 6. Animal rule (FDA) 6 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits Approval based on evidence of effectiveness from studies in animals • Safety must have been established • Adequate well-controlled animal studies to establish benefit in humans Requirements: • Understanding of mechanism of toxicity and prevention/reduction by product • Demonstrated in well-characterised animal model/in more than one animal species predictive of human situation • Animal study endpoint relates to desired benefit in humans • Data allow the selection of effective human dose Guidance for Industry, Product Development Under the Animal Rule. May 2014 and October 2015
  • 7. Rabbit efficacy challenge model • Most commonly used/accepted anthrax model (GUP & PEP) • Recommended standardised schedule for testing Anthrax Vaccines for non- inferiority to AVA • NZW rabbits, 20-32 per group • 2 vaccinations of 1/16 of a human dose of AVA • Challenge with 200 LD50s of B. anthracis Ames via aerosol route • Secondary readout serology (TNA NF50) day 0, 14, 28, 35, 42, 56, 69 7 Day 0 14 28 35 42 56 69,70 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
  • 8. Development of reagents and assays • Challenge spores: • Production • Characterisation • LD50 estimation • Assay reagent generation: • Rabbits vaccinated with anthrax vaccine • Blood samples processed into large volumes of serum • Assay development: • Cell-based TNA adapted to measure immune responses in rabbits • ELISA to measure antibody titres in rabbits • New assays to study cell-mediated immunity Efficacy of Anthrax Vaccines in rabbit models8 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits Rabbit efficacy challenge model
  • 9. GUPApplication –AVP &AVA • 2 dose regime replicated initially • 20 rabbits vaccinated with 1/16 dose AVP • 20 rabbits vaccinated with 1/16 dose AVA • 4 rabbits vaccinated with saline 9 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits Day 0 14 28 35 42 56 70 84
  • 10. Pre-challenge ear bleeds • Serum: • TNA • Analysis in anti-PA, anti-LF and anti-EF ELISA • Whole heparinised blood used to develop CMI assays: • Flow cytometry – CD4, CD8, CD45 • Stimulate lymphocytes with rPA or ConA, RT-PCR for cytokines • Whole blood cell count and viability, NC200 image cytometer • Baseline blood streak 10 Efficacy of Anthrax Vaccines in rabbit models – Kelly Thomas GUPApplication –AVP &AVA
  • 11. Post-challenge samples • Samples to calculate presented dose • Ear bleed at onset of clinical signs? • Animals monitored for clinical observations, temperature, weight • 2ml ear bleeds taken where possible • Serum stored – trigger to treat ECL assay under development • Post-mortem blood streak – samples taken after all deaths (as a result of challenge, euthanasia at humane endpoint or at scheduled cull). Allows cause of death confirmation 11 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits GUPApplication –AVP &AVA
  • 12. Necropsy • Carried out on all survivors • Carried out for animals that died mid-study where feasible • Blood: • Serum – for TNA and ELISA • Bacteriology • Lungs and lymph nodes: • Bacteriology • Histopathology • Spleens: • Bacteriology • Histopathology 12 GUPApplication –AVP &AVA Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
  • 13. 0 0.2 0.4 0.6 0.8 1 0 7 14 21 28 35 42 49 56 63 70 NF50 Study day Median pre-challenge TNA NF50s AVP AVA 13 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits GUPApplication –AVP &AVA
  • 14. 14 Post-challenge survival Days post-challenge 0 2 4 6 8 10 12 14 %survival 0 20 40 60 80 100 AVP AVA Saline AVP AVA Saline GUPApplication –AVP &AVA Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
  • 15. 15 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits GUPApplication –AVP &AVA 0 20 40 60 80 100 0 2 4 6 8 10 12 14 Clinicalscoreas%ofmaximumpossiblescore Time (days post-challenge) Clinical score AVP AVA Saline
  • 16. Blood & tissues • Bacteriology • Blood and spleen of survivors negative for bacteria • Bacteria enumerated in blood of some animals that died - highest level in control. Some vaccinated animals positive, some negative • All lungs contained bacteria. Highest in controls • Highest bacterial counts in control spleen, some others positive • Lymph nodes (where available) all <LOD • Histology • Control animal showed high level of bacteraemia, some lesions in spleen and lung • More severe lesions in vaccinated animals • More tissues in AVA group classified as ‘within normal limits’ 16 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits GUPApplication –AVP &AVA
  • 17. • Study design modified to 3 doses and included generic rPA vaccine • 10 rabbits vaccinated with 1/16 dose AVP • 10 rabbits vaccinated with 1/16 dose AVA • 10 rabbits vaccinated with 10mg rPA with alum • 4 rabbits vaccinated with saline 17 Day 0 28 56 70 98 112 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits 3 dose GUP study –AVP,AVA& rPA
  • 18. 0 0.4 0.8 1.2 1.6 2 0 14 28 42 56 70 84 98 TNANF50 Study day Median pre-challenge NF50s AVP AVA rPA&alum 18 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits 3 dose GUP study –AVP,AVA& rPA
  • 19. 19 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits 3 dose GUP study –AVP,AVA& rPA Post-challenge survival Days post-challenge 0 2 4 6 8 10 12 14 %survival 0 20 40 60 80 100 AVP AVA rPA&alum Saline
  • 20. 20 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits 3 dose GUP study –AVP,AVA& rPA 0 20 40 60 80 100 0 2 4 6 8 10 12 14 Clinicalscoreas%ofmaximumpossiblescore Time (days post challenge) Clinical score AVP AVA rPA&alum Saline
  • 21. Blood & tissues • Bacteriology: • Bacteria in blood of controls. Most survivors negative • Spleens of control animals all positive. Survivors negative • Lungs of control animals contained highest level of bacteria. Some survivors’ lungs positive, some negative • Histopathology: • Visible bacilli in most control spleens and lungs, not survivors • Moderate lesions of disease in control spleens, absent/milder in survivors • Moderate inflammation in lungs of controls. Some survivors showed distinct lesions, limited/no inflammation in most survivors – especially rPA & alum group • Most survivors showed tissue hyperplasia/cell infiltration - reactive/protective? 21 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits 3 dose GUP study –AVP,AVA& rPA
  • 22. • Study design based on previous publications • Rabbits challenged with 200 LD50s Ames spores • 30 rabbits received 50mg/kg levofloxacin once a day for 7 days from day 0 • 10 rabbits vaccinated with 1/16 dose AVP on day 0 and day 7 • 10 rabbits vaccinated with 1/16 dose AVA on day 0 and day 7 • 10 rabbits received saline injections on day 0 and day 7 • 4 controls 22 Day 0 7 16 21 30 PEPApplication –AVP &AVA Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
  • 23. Samples • Enumeration of challenge material • Ear bleeds taken on day 0, 7, 16 and 21 from all remaining animals • TNA/ELISA • ECL assay • Streak plates • Necropsy carried out on all survivors on day 30 (or some mid-study deaths): • Serum • Blood for bacteriology • Spleen and lungs for bacteriology and histology 23 Dilution OD Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits PEPApplication –AVP &AVA
  • 24. 24 Post-challenge survival Days post-challenge 0 5 10 15 20 25 30 %survival 0 20 40 60 80 100 AVP AVA Antibiotics Saline AVP & Antibiotic AVA & Antibiotic Antibiotic Saline PEPApplication –AVP &AVA Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
  • 25. 25 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits PEPApplication –AVP &AVA 0 20 40 60 80 100 0 5 10 15 20 25 30 Clinicalscoreas%ofmaximumpossiblescore Time (days post challenge) Clinical score AVP & Antibiotic AVA & Antibiotic Antibiotic Saline
  • 26. Blood & tissues • Bacteriology: • Blood streak plates positive from most premature deaths. Negative for survivors • Lungs contained bacteria when animals died mid-study. Lungs of survivors low/negative • Bacteria in spleens of most mid-study deaths, survivors negative • Histopathology: • Visible bacteria in tissues of some premature deaths • Sporadic lung, spleen and lymph node lesions. Generally worst in control animals, moderate in antibiotic group – milder in vaccinated groups • Different changes seen in vaccinated animals compared to controls/antibiotic only – some may be protective response rather than disease related 26 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits PEPApplication –AVP &AVA
  • 27. Rabbit studies - summary • Rabbit model – widely used to study AV efficacy in US • Developed gold standard rabbit model in-house at PHE • Efficacy of range of Anthrax Vaccines demonstrated and compared • Supplementary information gathered on tissue pathology & bacterial burden • Developed assays to study immune responses/correlates of protection and for rapid toxin detection – important for well-characterised model • Modified GUP schedule as appropriate for test vaccine (can also modify route) • Adapted model to show PEP benefits (can apply to new and existing vaccines) Presentation title - edit in Header and Footer27 Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits
  • 28. Acknowledgements Vaccine Research Group • Sue Charlton • Bassam Hallis • Phillip Brown • Ines Vitoriano • Nadina Wand • Anna Pang • Kim Steeds • Debbie Powell • Ross Fothergill • Emma Kennedy • Emily Hughes • Rebecca Cobb • Ester Schallinger • Charlotte Ford • Marilyn Aram • Tom Slocombe • Shea Creaven • Lara Mason • Jessica Fretwell • Julia Sung • Simon Eastham 28 Immunoassay Group • Mary Matheson Biodefense and Preclinical Evaluation Group • Julia Vipond • Simon Funnell • Helen Shuttleworth, Kerry Godwin, Nicola Jones Influenza Research Group • Karen Gooch, Jennifer Logue, Kathryn Ryan Biological Investigations Group • Irene Taylor • Graham Hatch • Susan Ryrie Efficacy Assessment of Anthrax Vaccines and Therapeutics in Rabbits